Publications in collaboration with researchers from KU Leuven (22)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

2023

  1. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  2. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

    Breast Cancer Research, Vol. 25, Núm. 1

2022

  1. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  2. Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

    Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077

  3. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  4. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

    npj Breast Cancer, Vol. 8, Núm. 1

  5. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    npj Breast Cancer, Vol. 8, Núm. 1

2021

  1. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    Breast Cancer Research, Vol. 23, Núm. 1

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156

  4. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  5. Sacituzumab govitecan in metastatic triple-negative breast cancer

    New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541

  6. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

    Breast Cancer Research and Treatment, Vol. 187, Núm. 1, pp. 155-165

  7. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

  2. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  3. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

    Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172

  4. Reimagining global oncology clinical trials for the postpandemic era: A call to arms

    JCO Global Oncology, pp. 1357-1362

2018

  1. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

    Cancer Treatment Reviews, Vol. 70, pp. 190-198